Products for Research Use Only
RegisterLogin

BC-DXI-843

CAT: 0804-HY-136431-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-136431-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer[1].
CAS Number
2421117-98-6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Aminoacyl-tRNA Synthetase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bc-dxi-843.html
Concentration
10mM
Purity
99.76
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2
Molecular Formula
C28H26N4O4S2
Molecular Weight
546.66
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Aneesh Sivaraman, et al. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J Med Chem. 2020 May 28;63 (10) :5139-5158.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-125402-01GSK-843
HY-109125SPK-843
HY-W999726CRBN ligand-843
HY-P991331BC-010
HY-D2953BC-CPY
HY-W128219-01BC-NH2
HY-119288-01BC-23
HY-149514BC-05
HY-129087-01BC-​1258
HY-107053BC-1175

Alternative Products

CatalogName
MBS3611933-01BC-DXI-843
GTR19240116BC-DXI-32982
T11474GSK-843
GTR19154278-01GSK'843

Popular Products